Artrya Limited (AU:AYA)
ASX:AYA
Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.10
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$4.10
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.61 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$780.32M
Enterprise ValueAU$488.88M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Aug 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding162,906,620
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside48.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)AU$6.45M
Bulls Say, Bears Say
Bulls Say
Focused AI Cardiovascular SoftwareArtrya's core product is AI-driven coronary angiography analysis, a specialized clinical workflow tool. That focused clinical niche aligns with structural demand for decision‑support in cardiology, supports recurring hospital adoption, and can create durable commercial hooks once validated and integrated.
Low Financial LeverageA low-debt balance sheet reduces refinancing and interest risks and gives management flexibility to fund clinical trials and product commercialization. This structural strength supports sustained R&D investment without immediate solvency pressure, lengthening runway for execution.
Early Revenue TractionReported revenue after prior near-zero levels and a large percentage increase signals initial commercial adoption. While absolute dollars are small, durable fundamental value lies in proving go‑to‑market capability and starting customer references that can be scaled over multiple quarters.
Bears Say
Sustained Cash BurnConsistent negative operating and free cash flow indicate the business remains cash‑consuming. Over the medium term this creates reliance on external capital, risks dilution, and can constrain the pace of commercial rollout or regulatory activities if funding becomes scarce.
No Demonstrated Operating LeveragePersistent large losses and extremely weak margins show the company has not yet converted R&D and sales investment into scalable, margin-accretive revenue. Without clearer improvement in unit economics, sustained losses may persist as revenue scales, pressuring long‑term viability.
Eroding Equity And Negative ROEDeclining shareholders' equity and negative ROE reflect ongoing value erosion from losses. Over months this undermines capital efficiency and investor confidence, making future fundraising costlier and increasing governance pressure if profitability is not restored.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.60 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$780.32M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 66 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.06.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 162,906,620 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (48.78% Upside)
AU$6.10 (48.78% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$4.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(48.78% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
Options Prices
Currently, No data available
---